Greg Guyer, Ph.D, joined 博彩平台网址大全 in May 2020 and currently serves as our Chief Technical Officer, responsible for overseeing our manufacturing, process development, quality, supply chain, engineering and analytical chemistry departments.
From 2015 to 2019, Dr. Guyer served in a number of increasingly responsible positions at Bristol Myers Squibb (BMS), primarily leading all of operations and biologic development. Prior to BMS, he worked for Merck & Co., Inc., from 1994 to 2015, leading various global organizations in biologic and pharmaceutical operations, quality, regulatory, emerging markets strategy and enterprise systems.
Dr. Guyer earned a Ph.D. in analytical chemistry from American University, a B.S. in chemistry from the University of Georgia and an M.B.A. from Lehigh University. He currently serves on the Board of Directors for the University of Georgia Research Foundation. In addition, Dr. Guyer also serves as executive Leader Liaison to the 博彩平台网址大全 PRIDE Employee Resource Group.
We maximize the impact of genetic innovation to develop transformative therapies.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.
Learn More Our Pipeline ⌃